- Home
- ANVS
ANVS
Annovis Bio Inc.
as 11-15-2024 4:00pm EST
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | MALVERN |
| Market Cap: | 110.4M | IPO Year: | 2020 |
| Target Price: | $29.67 | AVG Volume (30 days): | 261.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.53 - $22.49 | Next Earning Date: | 11-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Annovis Bio Inc. News
ANVS Breaking Stock News: Dive into ANVS Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)
GlobeNewswire
6 days ago
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update
Simply Wall St.
6 days ago
Will Annovis Bio (NYSE:ANVS) Spend Its Cash Wisely?
GlobeNewswire
10 days ago
Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist
GlobeNewswire
17 days ago
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio
MT Newswires
23 days ago
Maxim Upgrades Annovis Bio to Buy From Hold, Price Target is $25
GlobeNewswire
a month ago
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024
GuruFocus.com
a month ago
Annovis Bio Shows Promise on FDA Clearance for Alzheimer's Drug
Compare ANVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANVS Annovis Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.